A Study of LY3041658 in Participants With Skin Diseases

• Status: Completed
• Trial end date: 2019-03-19
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to investigate the safety and tolerability of the study drug known as LY3041658 in participants with certain types of skin diseases. The study will measure how the body absorbs, breaks down and gets rid of LY3041658. It will last about 127 days for each participant, not including screening. This study is for research purposes only, and is not intended to treat any medical condition.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Investigator confirmed diagnosis of certain skin diseases for at least 6 months.

• Active skin lesions that are not responding to standard therapies.

• Willing to undergo pre- and post-treatment skin biopsies of lesions.

Exclusion Criteria:

• Have other skin diseases that may interfere with evaluation of the specified skin disease being studied.